LONDON (AP) – Drugmaker Sanofi says that its dengue vaccine, the world’s first, could put people at risk of severe disease if they haven’t previously been infected, according to new long-term data.
In a statement, Sanofi said it had recently examined six years of patient data. Scientists concluded that while the vaccine protects people against further infection if they’ve already been exposed to dengue, that’s not the case for people who haven’t previously been sickened by the disease.
“For those not previously infected by dengue virus…the analysis found that in the longer term, more cases of severe disease could occur following vaccination,” Sanofi said. “These findings highlight the complex nature of dengue infection.”
People who catch dengue more than once can be at risk of a hemorrhagic version of the disease. The mosquito-spread disease is found in tropical and sub-tropical climates worldwide. It causes a flu-like disease that can cause joint pain, nausea, vomiting and a rash. In severe cases, dengue can cause breathing problems, hemorrhaging and organ failure.
The World Health Organization says that about half the world’s population is at risk of dengue and estimates that about 96 million people are sickened by the viral infection every year.
